Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration
Open Access
- 17 February 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Eye
- Vol. 34 (12), 2249-2256
- https://doi.org/10.1038/s41433-020-0799-y
Abstract
Background/objectives To investigate the association between optical coherence tomography (OCT) markers of lesion activity and changes in visual acuity (VA) during anti-vascular endothelial growth factor (anti-VEGF) therapy of eyes diagnosed with neovascular age-related macular degeneration (nAMD); and how VA and OCT markers are considered in physicians’ decision to retreat with anti-VEGFs. Subjects/methods Retrospective, non-comparative, non-randomised cohort study involving electronic medical record data collected from 1190 patient eyes with nAMD diagnosis at two sites in the United Kingdom. Two sub-cohorts consisting of 321 and 301 eyes, respectively, were selected for analyses. Results In 321 eyes, absence of IRF or SRF at ≥2 clinic visits resulted in a gain of five ETDRS letters from baseline, compared with two letters gained in eyes with p = 0.006) or SRF (p = 0.042). Anti-VEGF treatment was administered at 421 clinic visits, and 308 visits were without treatment. Comparing treatment visits with non-treatment visits, the maximum difference in frequency of OCT markers of lesion activity were for intraretinal fluid (IRF; 24% versus 5%) and subretinal fluid (SRF; 32% versus 5%). Pigment epithelial detachment (PED) was reported in 58% of treatment visits compared with 36% in non-treatment visits. VA loss was not a consistent trigger for retreatment as it was present in 63% of injection visits and in 49% of non-injection visits. Conclusions Retreatment decision making is most strongly influenced by the presence of IRF and SRF and less by the presence of PED or VA loss.Funding Information
- Novartis Pharma AG, Basel, Switzerland
This publication has 30 references indexed in Scilit:
- REFRACTORY INTRARETINAL OR SUBRETINAL FLUID IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIZUBIMABRetina, 2015
- Time to Initial Clinician-Reported Inactivation of Neovascular Age-Related Macular Degeneration Treated Primarily with RanibizumabOphthalmology, 2014
- Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degenerationBritish Journal of Ophthalmology, 2014
- Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaborationInternational Journal of Surgery, 2014
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments TrialsOphthalmology, 2013
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR StudyOphthalmology, 2009
- Ranibizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- Tolerability and Efficacy of Multiple Escalating Doses of Ranibizumab (Lucentis) for Neovascular Age-Related Macular DegenerationOphthalmology, 2006